<DOC>
	<DOCNO>NCT02699450</DOCNO>
	<brief_summary>This multiple-center , multiple-dose , randomize , active comparator-controlled , double-masked , three parallel group , 28-week study participant CI-DME . Only one eye select study eye . Where eyes meet eligibility criterion , eye bad best correct visual acuity ( BCVA ) define study eye . Participants randomize arm group ( 1:1:1 ) total duration study approximately 32 week .</brief_summary>
	<brief_title>A Phase 2 Study RO6867461 Participants With Center-Involving Diabetic Macular Edema ( CI-DME ) ( BOULEVARD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Macular edema associate diabetic retinopathy ( DR ) Decreased visual activity ( VA ) attributable primarily DME Diagnosis diabetes mellitus ( DM ) Proliferative diabetic retinopathy ( PDR ) Cataract surgery within 3 month Baseline , previous intraocular surgery Uncontrolled glaucoma Current history ocular disease study eye DME Major illness major surgical procedure within 1 month prior Day 1 Uncontrolled blood pressure Glycosylated hemoglobin ( HbA1c ) great ( &gt; ) 10 percent ( % ) screening Untreated diabetes mellitus initiation oral antidiabetic medication insulin within 4 month prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>